Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Announcing the $256 million deal, the New York-based biotech firm vowed to comply with 23andMe’s privacy policy, which was a ...

Biotechnology has emerged as a driving force in transforming healthcare. Over the past few decades, the integration of biology with advanced technology has led to significant breakthroughs. These ...

Wilson's new company, Philadelphia-based Gemma Biotherapeutics, plans to start testing gene therapies in Brazil this year.

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Genetic data was on the auction block, and a U.S. biotech company ponied up the cash. New York-based Regeneron Pharmaceuticals announced on Monday that it has purchased DNA testing company 23andMe ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...

A biotech company has announced plans to acquire 23andMe after the genetic testing company filed for Chapter 11 bankruptcy.